ANTHONY W. IRELAND, M.B.; JOHN S. CLUBB, M.B.; FRANCIS C. NEALE, PH.D.; SOLOMON POSEN, M.D., F.R.A.C.P.; THOMAS S. REEVE, M.B.
Thirty patients with surgical hypoparathyroidism are presented. All received vitamin D therapy in the form of calciferol. Biochemical control, as defined by arbitrary criteria, was achieved in only nine patients for a total period of 26 patient-years.
The mean controlling dose of calciferol was 2.12 mg/day; the mean dose producing hypercalcemia in 16 patients was 3.28 mg/day. No patient was controlled on less than 1.25 mg/day, and only two patients were controlled on a calciferol dose of 1.25 mg/day. Every patient receiving calciferol doses greater than 2.50 mg/day became hypercalcemic. A mechanism is suggested for the proximity between "controlling" and "intoxicating" doses of calciferol in hypoparathyroidism. The documented periods of hypercalcemia lasted 1 to 6 weeks after withdrawal of calciferol.
No significant differences were found between the calciferol requirements of euthyroid and hypothyroid patients.
Learn more about subscription options.
Register Now for a free account.
IRELAND AW, CLUBB JS, NEALE FC, POSEN S, REEVE TS. The Calciferol Requirements of Patients with Surgical Hypoparathyroidism. Ann Intern Med. 1968;69:81–89. doi: 10.7326/0003-4819-69-1-81
Download citation file:
Published: Ann Intern Med. 1968;69(1):81-89.
Endocrine and Metabolism, Parathyroid Disorders.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only